Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Eribulin (NSC# 707389) in Recurrent or Refractory Osteosarcoma

NCT02097238 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02097238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02097238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Eribulin (NSC# 707389) in Recurrent or Refractory Osteosarcoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2014
Completion date
March 31, 2020
Enrollment
19 (actual)
Sites
119

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent osteosarcoma